Business Description
Allogene Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US0197701065
Description
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.43 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.33 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -3.32 | |||||
| Beneish M-Score | -1.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 2.8 | |||||
| 3-Year EPS without NRI Growth Rate | 8.6 | |||||
| 3-Year FCF Growth Rate | -0.5 | |||||
| 3-Year Book Growth Rate | -26.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 9.15 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 166.32 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.92 | |||||
| 9-Day RSI | 27.49 | |||||
| 14-Day RSI | 33.12 | |||||
| 3-1 Month Momentum % | -8.11 | |||||
| 6-1 Month Momentum % | 7.09 | |||||
| 12-1 Month Momentum % | 5.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.35 | |||||
| Quick Ratio | 9.35 | |||||
| Cash Ratio | 8.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.3 | |||||
| Shareholder Yield % | 1.68 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -625246.51 | |||||
| Net Margin % | -659137.21 | |||||
| FCF Margin % | -506806.98 | |||||
| ROE % | -55.89 | |||||
| ROA % | -44.6 | |||||
| ROIC % | -121.34 | |||||
| 3-Year ROIIC % | 24 | |||||
| ROC (Joel Greenblatt) % | -173.96 | |||||
| ROCE % | -45.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1890 | |||||
| PB Ratio | 0.85 | |||||
| Price-to-Tangible-Book | 0.85 | |||||
| EV-to-EBIT | -0.69 | |||||
| EV-to-EBITDA | -0.73 | |||||
| EV-to-Revenue | 4415.14 | |||||
| EV-to-Forward-Revenue | 3797.03 | |||||
| EV-to-FCF | -0.87 | |||||
| Price-to-Net-Current-Asset-Value | 2.22 | |||||
| Price-to-Net-Cash | 2.39 | |||||
| Earnings Yield (Greenblatt) % | -144.93 | |||||
| FCF Yield % | -54.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Allogene Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.043 | ||
| EPS (TTM) ($) | -1.56 | ||
| Beta | 1.05 | ||
| 3-Year Sharpe Ratio | -0.7 | ||
| 3-Year Sortino Ratio | -0.95 | ||
| Volatility % | 77.49 | ||
| 14-Day RSI | 33.12 | ||
| 14-Day ATR ($) | 0.181505 | ||
| 20-Day SMA ($) | 2.2325 | ||
| 12-1 Month Momentum % | 5.84 | ||
| 52-Week Range ($) | 1.83 - 5.775 | ||
| Shares Outstanding (Mil) | 209.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Allogene Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Allogene Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Allogene Therapeutics Inc Frequently Asked Questions
What is Allogene Therapeutics Inc(ALLO)'s stock price today?
The current price of ALLO is $1.89. The 52 week high of ALLO is $5.78 and 52 week low is $1.83.
When is next earnings date of Allogene Therapeutics Inc(ALLO)?
The next earnings date of Allogene Therapeutics Inc(ALLO) is 2025-03-14 Est..
Does Allogene Therapeutics Inc(ALLO) pay dividends? If so, how much?
Allogene Therapeutics Inc(ALLO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers